miércoles, 16 de noviembre de 2016

Human trials begin for Army-developed Zika vaccine | Health.mil

Human trials begin for Army-developed Zika vaccine | Health.mil

Human trials begin for Army-developed Zika vaccine

The Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito – Aedes aegypti, shown here, and Aedes albopictus. The same mosquitoes spread dengue and chikungunya viruses. Mosquitoes become infected when they feed on a person already infected with the virus. Infected mosquitoes can then spread the virus to other people through bites. (Centers for Disease Control and Prevention photo by James Gathany)
The Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito – Aedes aegypti, shown here, and Aedes albopictus. The same mosquitoes spread dengue and chikungunya viruses. Mosquitoes become infected when they feed on a person already infected with the virus. Infected mosquitoes can then spread the virus to other people through bites. (Centers for Disease Control and Prevention photo by James Gathany)

WASHINGTON — A clinical trial began recently at the Walter Reed Army Institute of Research, where 75 participating healthy adults were vaccinated with a Zika virus vaccine that the institute's scientists developed earlier this year, Walter Reed officials announced.
The Phase 1 trial will test the safety and immunogenicity – the ability of the vaccine to trigger an immune response in the body – of the purified, inactivated Zika virus vaccine called ZPIV. The vaccine is being tested at WRAIR's Clinical Trial Center in Silver Spring, Maryland.
"The Army has moved efficiently from recognizing Zika virus as a threat, producing ZPIV for use in animals and demonstrating its effectiveness in mice and monkeys, producing ZPIV for human testing, and now initiating clinical trials to establish its safety and build the case for subsequent efficacy trials," Army Col. (Dr.) Nelson Michael, director of WRAIR's Military HIV Research Program, or MHRP, and Zika program co-lead, said in a statement.
Efficacy refers to the vaccine's ability to demonstrate a health effect when tested in a clinical trial.
"All of this," he added, "was done in 10 months."
Dr. Kayvon Modjarrad, Zika program co-lead and associate director for emerging infectious disease threats at WRAIR's MHRP, said the Army was able to move so quickly in developing, manufacturing and testing a Zika vaccine "because of its extensive experience with this vaccine platform and longstanding investments in the understanding and mitigation of flaviviruses like yellow fever, dating back to the founding of WRAIR."
WRAIR officials say this study is part of the Defense Department response to the ongoing Zika outbreak in North and South America and Southeast Asia.
For service members, there are concerns about infection during deployment and travel, but also in the continental United States, where most military installations are concentrated in southern states. There, climate conditions and mosquito populations favor Zika transmission, WRAIR officials say.
As of Nov. 2, according to the Centers for Disease Control and Prevention, 149 cases of Zika infection were confirmed in the military health system, including four pregnant service members and one pregnant family member.
Zika infection during pregnancy, the CDC says, can cause a birth defect of the brain called microcephaly and other severe fetal brain defects.
Other problems have been detected among fetuses and infants infected with Zika virus before birth, such as defects of the eye, hearing deficits and impaired growth. And reports have increased about Guillain-Barré syndrome, an uncommon sickness of the nervous system, in areas affected by Zika, CDC says.
But even Zika infections without symptoms "can lead to severe birth defects and neurological complications," Zika study principal investigator Army Maj. (Dr.) Leyi Lin said, adding, "A safe and effective Zika vaccine that prevents infection in those at risk is a global public-health priority."
Flaviviruses like Zika are found mainly in mosquitoes and ticks and cause widespread morbidity and mortality worldwide. Other mosquito-transmitted viruses that are members of the flavivirus genus include yellow fever, or YF, dengue fever, Japanese encephalitis, or JE, and West Nile viruses, according to the CDC web page.
"We want to assess the safety and immune response of the ZPIV vaccine in JE and yellow fever YF vaccine recipients because these vaccines may alter the response to the ZPIV vaccine," Lin said.
"Uniquely," he added, "illness as a result of natural infection from JE, YF or Zika could be more severe when prior flavivirus infection or vaccination exists. Our study assesses co-vaccination to learn how to reduce risk when protecting against circulating flaviviruses."
This is important for service members who are vaccinated against other flaviviruses and then stationed in or deployed to areas where Zika is becoming endemic, WRAIR scientists say.
WRAIR's inactivated flavivirus vaccine platform was the same technology the institute used to create its Japanese encephalitis vaccine, licensed in 2009.
An earlier preclinical study found that rhesus monkeys vaccinated with ZPIV developed a strong immune response and were protected against two strains of Zika virus.
The National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, helped identify the viral strain used in the ZPIV vaccine, supported the preclinical safety testing and is sponsoring the conduct of this trial.
WRAIR, NIAID and the Department of Health and Human Services' Biomedical Advanced Research and Development Authority, or BARDA, have established a joint research collaboration agreement to support the vaccine's development.
The Pilot Bioproduction Facility at WRAIR manufactured the ZPIV vaccine being used in Phase 1 clinical studies, and the Army recently signed a cooperative research and development agreement to transfer the ZPIV technology to Sanofi Pasteur to explore larger scale manufacturing and advanced development. BARDA recently awarded a six-year contract to Sanofi Pasteur to further develop this vaccine to licensure, according to the WRAIR release. 
Disclaimer: Re-published content may have been edited for length and clarity. Read original post.

Genome Center tracking and sequencing - making a difference in health care

Nathan Watt, a research associate at the Uniformed Services University of the Health Sciences, closely monitors data on a next-generation sequencer in The American Genome Center at the university. This sequencing helps pinpoint genetic mutations that could serve as biomarkers, which can better predict disease risks and outcomes. TAGC is one of four academic genome centers in the U.S. and the only genome center in the federal system.  (DoD photo by Sarah Marshall)
The American Genome Center at USU aims to study large populations by quickly sequencing thousands of genomes
Related Topics:Medical Research and DevelopmentTechnology

A decade of progress in Women’s health, cancer research

Navy Lt. Cmdr. Denise Thigpen, director, Breast Imaging Center at the Murtha Cancer Center at Walter Reed Bethesda, reads two mammograms of a patient. (Courtesy photo)
New discoveries at the Murtha Cancer Center have researchers encouraged about Women’s cancer research
Related Topics:Women's HealthMedical Research and DevelopmentPatient Safety

Immunization University and Project Immune Readiness Certificate Retrieval Instructions

Related Topics:Immunization Healthcare

DoD will conduct flu immunization program without FluMist

Navy Hospital Corpsman 2nd Class Carly Marcum, administers an influenza vaccination to a Sailor aboard USS John C. Stennis. This flu season, the DoD’s entire supply of flu vaccine will be injectable. (U.S. Navy photo by Mass Communication Specialist Seaman Cole C. Pielop)
The intranasal flu vaccine known as FluMist will not be available at DoD facilities or covered by TRICARE during the 2016-17 influenza season because the Centers for Disease Control and Prevention recommended against using it this year
Related Topics:ImmunizationsImmunization Healthcare

Office of Naval Research developing new ways to protect injured limbs

Office of Naval Research Logo
The Office of Naval Research is sponsoring work to develop a breakthrough medical wrap, that will not only cover injured limbs, but also mitigate damage and protect tissue for up to three days
Related Topics:Research and InnovationMedical Research and Development

What the experts want you to know about the HPV vaccine

About 80 million people are infected with HPV right now in the United States. Vaccines are currently available for both males and females to help prevent the virus, which can be linked to various cancers, such as cervical cancer. (U.S. Air Force photo by Staff Sgt. Benjamin W. Stratton)
HPV is a virus that can be linked to a range of health issues, including cervical cancer. Immunization experts are encouraging people to learn more about the vaccines that help prevent this often undetected virus
Related Topics:Women's HealthChildren's HealthImmunizationsImmunization Healthcare

Morbidity and Mortality Weekly Report (MMWR), Zika Virus Disease Cases: January 1 – July 31, 2016

The Morbidity and Mortality Weekly Report (MMWR) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.
Related Topics:Zika Virus

OPM Guidance on Workplace Flexibilities and Authorities for Dealing with the Zika Virus

The U.S. Office of Personnel Management (OPM) reminds agencies that a wide range of human resources (HR) policies and flexibilities are available to assist employees and agencies in dealing with the Zika virus. This guidance provides information regarding the leave and other workplace flexibilities and authorities available for these purposes.
  • Identification #: N/A
  • Date: 9/23/2016
  • Type: Guidelines
  • Topics: Zika Virus

Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components

The U.S. Food and Drug Admnistration is issuing this guidance for blood establishments that collect Whole Blood and blood components for immediate implementation in accordance with 21 CFR 10.115(g)(2).
  • Identification #: N/A
  • Date: 9/23/2016
  • Type: Guidelines
  • Topics: Zika Virus

Mosquito Control & Bite Prevention: Educational Flipbook

Mosquitoes can spread viruses like Zika, chikungunya, and dengue.This flipbook gives basic information about mosquito control activities and how to protect from mosquito bites. Mosquito control approaches that incorporate community education, and mosquito surveillance and control are often called “integrated vector control.” A vector is an insect, like a mosquito, that can spread viruses.
Related Topics:Mosquito-Borne IllnessesPreventing Mosquito-Borne IllnessesChikungunyaDengueMalariaWest NileZika Virus

Detecting and Reporting DoD Cases of Acute Zika Virus Disease

Fact Sheet
This document provides guidance for detecting and reporting DoD cases of acute Zika Virus Disease
Related Topics:Zika VirusArmed Forces Health Surveillance Branch

DoDEA Influenza Vaccine Requirement


Army prepares to administer 1.6 million flu shots

Army Pvt. Jonathan Bowen (left), health care specialist with the 1st Special Troops Battalion, 1st Cavalry Division Sustainment Brigade, provides an influenza vaccination to another Soldier.
The goal is to immunize with flu shots at least 90 percent of service members and health care professionals by Dec. 15, 2016
Related Topics:Immunization HealthcareImmunizationsPreventive Health

Precision medicine offers individualized health care instead of “one-size-fits-all”

Dr. Mark Haigney discusses his views on precision medicine to researchers at the MHS Research Symposium on Aug. 17, 2016.
Precision medicine is an innovative approach that may revolutionize the way we improve health and treat diseases.
Related Topics:Medical Research and DevelopmentMHS Research SymposiumDoD/VA Sharing Initiatives

TBI milestone: Research program enrolls 15,000 participants

DVBIC researchers have collected long-term TBI recovery and outcomes information on veterans through the Department of Veterans Affairs TBIMS program since 2008. (U.S. Air Force photo by Tech. Sgt. Miguel Lara III)
The database collects standardized recovery and outcomes data on patients with TBIs serious enough to require hospitalization
Related Topics:Traumatic Brain InjuryMedical Research and Development

No hay comentarios:

Publicar un comentario